| First Author | Sehrawat S | Year | 2013 |
| Journal | Blood | Volume | 121 |
| Issue | 7 | Pages | 1145-56 |
| PubMed ID | 23243279 | Mgi Jnum | J:194608 |
| Mgi Id | MGI:5474402 | Doi | 10.1182/blood-2012-08-447409 |
| Citation | Sehrawat S, et al. (2013) A catalytically inactive mutant of the deubiquitylase YOD-1 enhances antigen cross-presentation. Blood 121(7):1145-56 |
| abstractText | Antigen presenting cells (APCs) that express a catalytically inactive version of the deubiquitylase YOD1 (YOD1-C160S) present exogenous antigens more efficiently to CD8(+) T cells, both in vitro and in vivo. Compared with controls, immunization of YOD1-C160S mice led to greater expansion of specific CD8(+) T cells and showed improved control of infection with a recombinant -herpes virus, MHV-68, engineered to express SIINFEKL peptide, the ligand for the ovalbumin-specific TCR transgenic OT-I cells. Enhanced expansion of specific CD8(+) T cells was likewise observed on infection of YOD1-C160S mice with a recombinant influenza A virus expressing SIINFEKL. YOD1-C160S APCs retained antigen longer than did control APCs. Enhanced crosspresentation by YOD1-C160S APCs was transporter associated with antigen processing (TAP1)-independent but sensitive to inclusion of inhibitors of acidification and of the proteasome. The activity of deubiquitylating enzymes may thus help control antigenspecific CD8(+) T-cell responses during immunization. |
